LyondellBasell
LYB
$0.00
+1.48%
LyondellBasell Industries N.V. is a global petrochemical producer, operating in the Basic Materials sector within the Chemicals industry, and is the world's largest producer of polypropylene and a major producer of polyethylene and propylene oxide. The company is a market leader in its core product segments, with a distinct competitive identity rooted in its massive scale, integrated operations, and significant North American production footprint. The current investor narrative is dominated by severe industry headwinds, as evidenced by a recent drastic dividend cut, and is further influenced by volatile feedstock costs and geopolitical risks impacting naphtha supply, creating a debate around the stock's cyclical positioning and the depth of the chemical industry downturn.…
LYB
LyondellBasell
$0.00
Related headlines
Investment Opinion: Should I buy LYB Today?
Rating: Hold. The core thesis is that LYB is a deeply cyclical stock in the throes of a severe downturn, where the substantial valuation discount is justified by collapsing fundamentals, making it premature to buy despite apparent cheapness.
Supporting Evidence: The stock trades at a distressed Price-to-Sales ratio of 0.46, a deep discount to historical norms and sector averages. However, this is warranted by a -25.3% YoY revenue decline and a gross margin collapse to 6.49%. While analyst consensus points to a recovery with an average EPS estimate of $7.17, implying significant upside, the current fundamentals do not support conviction in that timeline. The strong TTM FCF of $2.26B and recent 'Buy' upgrades from Citigroup and RBC Capital provide a floor, but are offset by the drastic dividend cut and negative trailing EPS of -$0.053.
Risks & Conditions: The two biggest risks are a further deterioration in chemical spreads extending losses, and a failure to stabilize revenues in the next two quarters. This Hold rating would upgrade to a Buy if the forward P/E of 7.47x is validated by a return to profitability (QoQ margin expansion) or if the stock approaches its 52-week low near $42, offering a larger margin of safety. It would downgrade to a Sell if quarterly revenue declines accelerate beyond -10% sequentially or if gross margins fail to recover above 10%. Relative to its history and the current cycle trough, the stock is fairly valued, as the deep PS discount accurately reflects the severe operational challenges.
Sign up to view all
LYB 12-Month Price Forecast
LYB is a classic late-cycle play where the fundamental pain is present but the valuation suggests much of it is priced in. The neutral stance reflects the high uncertainty in timing a cyclical turnaround; the strong cash flow and low PS ratio provide a floor, but the collapsing margins and negative earnings momentum advise caution. The stance would upgrade to bullish on concrete evidence of margin stabilization (gross margin >10% for two consecutive quarters) or a drop towards the $42 support level. It would turn bearish if quarterly revenues fall below $6.5B or if debt levels increase while FCF turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
10 analysts
Implied Upside
—
vs. current price
Analyst Count
10
covering this stock
Price Range
$0 - $0
Analyst target range
A cohort of 10 analysts provides coverage, with recent institutional ratings showing a mix of actions including upgrades to 'Buy' and 'Outperform' from Citigroup and RBC Capital in March 2026, alongside several 'Hold' or 'Neutral' reiterations, indicating a cautiously improving but still mixed sentiment. The average analyst EPS estimate for the coming period is $7.17, with a wide range from a low of $4.54 to a high of $9.57, reflecting significant uncertainty about the pace and magnitude of an earnings recovery; the wide target spread signals high uncertainty regarding the company's future trajectory, with the high target likely assuming a sharp cyclical rebound in margins and the low target pricing in a prolonged downturn.
Bulls vs Bears: LYB Investment Factors
The bull case rests on extreme valuation pessimism, strong underlying cash flow, and anticipated cyclical recovery, while the bear case is grounded in the harsh reality of collapsing margins, declining revenue, and management's defensive actions like the dividend cut. Currently, the bearish evidence holds stronger weight, as the fundamental deterioration (gross margin falling to 6.49%, revenue down -25.3% YoY) is severe and ongoing, outweighing the potential of a future rebound. The single most important tension in the investment debate is the timing and magnitude of the cyclical recovery in chemical margins versus the risk of a prolonged downturn that could further strain the balance sheet and challenge the dividend. The stock's fate hinges on whether LYB's massive scale and cash flow allow it to outlast the downturn before the valuation discount becomes justified by permanent impairment.
Bullish
- Deeply Undervalued Price-to-Sales: LYB trades at a trailing PS ratio of 0.46, which is near the bottom of its historical range and a significant discount to profitable chemical industry peers. This extreme discount prices in a severe, prolonged downturn, offering substantial upside if margins recover even modestly.
- Strong Free Cash Flow Generation: Despite posting a net loss, LYB generated $2.26 billion in trailing twelve-month free cash flow. This robust cash generation provides a crucial buffer to navigate the downturn, maintain its reduced dividend, and preserve financial flexibility.
- Analyst Expects Sharp EPS Rebound: The average analyst EPS estimate for the coming period is $7.17, a dramatic recovery from the current trailing EPS of -$0.053. This implies the market is expecting a significant cyclical recovery in profitability, with the high estimate reaching $9.57.
- Oversold Technical Condition: The stock is down 30.7% over the past three months and trades at just 66% of its 52-week high, near the lower third of its annual range. This steep decline suggests significant pessimism is priced in, potentially creating a contrarian opportunity.
Bearish
- Severe Profit Margin Collapse: Gross margin collapsed to 6.49% in Q4 2025 from 15.12% in Q3 2024, and the company reported a net loss of -$140 million. This dramatic compression indicates intense pricing pressure and weak demand, with no clear near-term bottom.
- Persistent Revenue Downtrend: Q4 2025 revenue of $7.09 billion declined -25.3% year-over-year, and the sequential quarterly trend from Q1 to Q4 2025 shows steady decreases. This confirms the cyclical downturn is deep and ongoing, not a transient event.
- Drastic Dividend Cut Signals Distress: The company recently slashed its dividend, a clear signal from management of severe industry headwinds and a need to conserve cash. This action erodes a key pillar of the investment thesis for income-oriented shareholders and reflects diminished confidence in near-term cash generation.
- Elevated Debt and Financial Leverage: LYB carries a debt-to-equity ratio of 1.58, which is elevated. While the current ratio of 1.77 shows adequate liquidity, high leverage during a cyclical trough increases financial risk and limits strategic optionality.
LYB Technical Analysis
The stock is in a pronounced downtrend, having fallen 30.73% over the past three months and 17.64% over the past month, decisively reversing the 28.86% gain it posted over the previous six months. Currently trading at $55.73, the price sits at just 66% of its 52-week high of $83.94 and is only 34% above its 52-week low of $41.58, indicating it is in the lower third of its annual range and signaling significant technical weakness and potential oversold conditions. Recent momentum is sharply negative and accelerating, with the 1-month decline of -17.64% far exceeding the 1-year loss of -4.57%, a divergence that suggests a breakdown from the prior recovery trend, further confirmed by a severe -45.70% relative strength versus the S&P 500 over three months. Key technical support is anchored at the 52-week low of $41.58, while immediate resistance lies at the recent breakdown level near the 52-week high of $83.94; a sustained break below $41.58 would signal a continuation of the bearish trend, while reclaiming the $70-$75 zone is needed to stabilize the chart. The stock's beta of 0.33 indicates it has been significantly less volatile than the broader market during this sell-off, which is atypical for a cyclical name and may suggest it is being treated as a defensive play within the sector, though its recent max drawdown of -37.1% highlights substantial absolute price risk.
Beta
0.36
0.36x market volatility
Max Drawdown
-37.1%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
-14.7%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | -20.7% | -1.3% |
| 3m | -33.0% | +13.6% |
| 6m | +20.2% | +9.0% |
| 1y | -14.7% | +19.1% |
| ytd | +20.2% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue is in a clear downtrend, with Q4 2025 revenue of $7.09 billion representing a -25.3% year-over-year decline, and the sequential trend from Q1 2025 ($7.68B) to Q4 2025 shows a steady quarterly decrease, indicating persistent demand and pricing pressure. The company is currently unprofitable, posting a Q4 2025 net income of -$140 million and a trailing twelve-month EPS of -$0.053, with gross margins severely compressed to 6.49% in Q4 from 15.12% in Q3 2024, reflecting a dramatic collapse in profitability amid the industry downturn. The balance sheet shows moderate liquidity with a current ratio of 1.77, but elevated financial leverage with a debt-to-equity ratio of 1.58; however, the company generated substantial trailing twelve-month free cash flow of $2.26 billion, which provides a crucial buffer to navigate the downturn, fund its reduced dividend, and maintain financial flexibility despite the net loss.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the negative net income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.46, while the forward-looking valuation can be inferred from the estimated revenue and market cap, suggesting the market is pricing the stock at a deep discount to sales due to current unprofitability. Compared to typical chemical industry valuations, a PS ratio of 0.46 represents a significant discount, as profitable chemical peers often trade above 1.0x sales; this discount is justified by LYB's negative margins and the cyclical downturn but may also present a deep-value opportunity if margins recover. Historically, LYB's current PS ratio of 0.46 is near the very bottom of its own historical range, which has seen ratios above 3.5x during peak cycles; trading at such a depressed level relative to its own history suggests the market is pricing in extremely pessimistic expectations for a prolonged downturn or fundamental deterioration.
PE
-18.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. LYB's profitability has evaporated, with Q4 2025 gross margin at 6.49% and net income of -$140 million, creating a cash burn risk if the downturn persists despite strong TTM FCF of $2.26B. The company carries elevated financial leverage with a debt-to-equity ratio of 1.58, which could become burdensome if EBITDA remains depressed. Revenue concentration in cyclical petrochemicals and dependence on volatile feedstock costs like naphtha, as highlighted by recent Middle East supply disruptions, expose operations to severe margin compression, evidenced by the sequential gross margin collapse from 15.12% to 6.49% in one quarter.
Market & Competitive Risks center on valuation compression and sector headwinds. Trading at a PS ratio of 0.46, LYB is priced for distress, but further multiple contraction is possible if the chemical industry downturn proves deeper or longer than expected, pressuring even this depressed valuation. The stock's beta of 0.33 suggests it has been less volatile than the market recently, but this may reflect its treatment as a 'value trap' rather than a defensive play, and its -37.1% max drawdown shows substantial absolute price risk. Competitive pressures and potential overcapacity in polyethylene and polypropylene markets could delay any pricing recovery, extending the period of negative earnings.
Worst-Case Scenario involves a prolonged global economic slowdown that suppresses chemical demand for multiple years, coupled with sustained high feedstock costs. This would lead to continued quarterly losses, a breach of debt covenants, a potential suspension of the already-reduced dividend, and a loss of investor confidence. In this adverse scenario, the stock could re-test its 52-week low of $41.58, representing a -25% downside from the current price of $55.73, and potentially fall further if the company's financial stability comes into question, leading to a realistic downside risk of -30% to -40%.
FAQ
The key risks are, in order of severity: 1) Cyclical & Operational Risk: A prolonged chemical industry downturn leading to further margin compression from the current 6.49% gross margin and continued revenue declines. 2) Financial Risk: Elevated debt-to-equity of 1.58 could pressure the balance sheet if losses persist, despite strong current FCF. 3) Commodity & Geopolitical Risk: Vulnerability to volatile feedstock costs, as seen with recent Middle East naphtha supply disruptions, which directly impact production costs. 4) Sentiment & Dividend Risk: The recent drastic dividend cut has damaged investor confidence and signals management's concern over near-term cash generation, increasing the stock's perceived risk profile.
The 12-month forecast is highly bifurcated, with a base case target range of $60-$75 (probability 50%), a bull case of $83-$95 (probability 25%), and a bear case of $41-$50 (probability 25%). The wide dispersion reflects the uncertainty around the chemical cycle. The base case, which is most likely, assumes a slow stabilization where LYB returns to modest profitability aligned with the analyst consensus EPS of $7.17. This forecast hinges on the critical assumption that quarterly revenue stops declining and gross margins begin a gradual recovery in the second half of 2026. Failure of this stabilization would trigger the bear case, while a sharper-than-expected rebound would activate the bull case.
LYB is statistically undervalued based on traditional multiples but the discount is justified by its current fundamentals. The trailing PS ratio of 0.46 is near the bottom of its historical range and represents a significant discount to profitable chemical peers. However, with negative earnings and collapsing margins, the stock is fairly valued for the depth of the cycle trough it is experiencing. The forward P/E of 7.5x, based on analyst estimates, suggests the market is pricing in a recovery, but that expectation is not yet supported by reported results. The valuation implies the market expects a significant earnings rebound; if that fails to materialize, the stock could be considered overvalued despite its low sales multiple.
LYB presents a high-risk, high-potential-reward opportunity that is not a good buy for most investors at this moment. For a speculative, deep-value investor with a multi-year horizon, the current Price-to-Sales ratio of 0.46 and analyst target upside (implied by a forward P/E of 7.5x on estimated EPS of $7.17) are compelling. However, the severe fundamental deterioration, including a -25.3% YoY revenue drop and a gross margin of 6.49%, means the timing of a recovery is highly uncertain. The drastic dividend cut further removes a key support. It could become a good buy on concrete signs of margin recovery or a further price drop towards the $41.58 support level.
LYB is suitable only for long-term, patient investors with a minimum holding period of 3-5 years. This is a cyclical recovery play, and historical cycles suggest turning points can take multiple quarters or years to manifest. The stock's low beta of 0.33 is misleading for its inherent business cycle volatility, and its lack of earnings visibility makes it a poor short-term trading vehicle. The recent dividend cut also reduces its appeal for income-focused long-term holders. Investors must be prepared to weather further downside and wait for the fundamental cycle to turn, making it unsuitable for short-term portfolios or those with low risk tolerance.